Abstract: This invention relates generally to non-ionic X-ray contrast agents. It further relates to the preparation of iodine chloride, a key reagent in the synthesis of non-ionic X-ray contrast agents such as iodixanol and iohexol. In particular, the iodine chloride is produced in a reaction involving iodine, sodium chlorate, and hydrochloric acid as the starting materials. The instant invention relates to a method of stabilizing aqueous iodine chloride solutions by adding about one to about four molar equivalents of sodium chloride relative to sodium chlorate to an aqueous reaction mixture of sodium chlorate, hydrochloric acid, and iodine.
Abstract: Nanodevice and method for in vivo monitoring and release of drugs are provided. The disclosed nanodevice is characterized in having a drug-loaded nanosphere that is capable of releasing the encapsulated drugs upon magnetically stimulation. The nanodevice may also be used as a contrast agent for in vivo imaging and monitoring the concentration and distribution of the released drugs and/or active compounds injected separately into a target site of a subject.
Type:
Application
Filed:
July 17, 2009
Publication date:
January 20, 2011
Applicant:
NATIONAL CHIAO TUNG UNIVERSITY
Inventors:
San-Yuan Chen, Shang-Hsiu Hu, Dean-Mo Liu, Kun-Ting Kuo
Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.
Type:
Grant
Filed:
April 25, 2008
Date of Patent:
January 4, 2011
Assignee:
Provectus Pharmatech, Inc.
Inventors:
H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
Abstract: This invention relates to sterilized cyanoacrylate adhesive compositions with x-ray imagining capabilities, methods of making such compositions, and methods of using such compositions.
Type:
Grant
Filed:
January 10, 2006
Date of Patent:
January 4, 2011
Assignee:
Henkel AG & Co. KGaA
Inventors:
Kenneth N. Broadley, Noeleen B. Swords, Clare P. Grealis
Abstract: The invention concerns a product consisting in an injection medicinal formulations comprising at least one compound to provide a viscous formulation, ethanol and at least one compound making said formulation opaque to X rays so as to control its delivery and its action. Said formulation is in particular useful for treating herniated invertebral discs but also in intervention having demonstrated the efficacy of pure ethanol: treatment of hepatocellular tumours or osteoid osteomas, renal cysts and arterial-veinous angiomas.
Type:
Application
Filed:
August 27, 2010
Publication date:
December 30, 2010
Inventors:
Jacques Theron, Marc d'Aboville, Christine Marie Joseph D' Aboville, Soline Alix Marie D'Aboville, Côme Philippe Guy D'Aboville, Quentin Bruno Pierre D'Aboville, Grégoire Michel Séverin D'Aboville
Abstract: The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.
Abstract: The present invention is directed to novel compositions and methods utilizing delivery agents comprising protein cages, medical imaging agents and therapeutic agents.
Type:
Application
Filed:
April 1, 2010
Publication date:
December 9, 2010
Applicant:
MONTANA STATE UNIVERSITY
Inventors:
Mark J. YOUNG, Trevor Douglas, Yves U. Idzerda
Abstract: Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound.
Abstract: The invention encompasses particles comprising metal atoms, methods of making the particles, and methods for using the particles. In particular, the particles may be used to image biological tissues or to deliver a bioactive agent.
Type:
Application
Filed:
October 9, 2008
Publication date:
November 25, 2010
Applicant:
THE WASHINGTON UNIVERSITY
Inventors:
Gregory M. Lanza, Samuel A. Wickline, Dipanjan Pan, Angana Senpan
Abstract: The present invention provides novel amino acid compounds useful in detecting and evaluating brain and body tumors. These compounds have the advantageous properties of rapid uptake and prolonged retention in tumors and can be labeled with halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. These compounds can also be labeled with technetium and rhenium isotopes using known chelation complexes. The compounds disclosed herein bind tumor tissues in vivo with high specificity and selectivity when administered to a subject. Preferred compounds show a target to non-target ratio of at least 2:1, are stable in vivo and substantially localized to target within 1 hour after administration. Preferred compounds include 1-amino-2-[18F]fluorocyclobutyl-1-carboxylic acid (2-[18F]FACBC) and 1-amino-2-[18F]fluoromethylcyclobutyl-1-carboxylic acid (2-[18F]FMACBC).
Abstract: The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease.
Abstract: The present invention is directed to an implantable device comprising a biocompatible and biodegradable matrix impregnated with a bioactive complex suitable for selectively targeting the lymphatic system, wherein the bioactive complex comprises one or more particle forming materials and one or more bioactive agents. The invention is further directed to methods of using and the process of preparing, the implantable device.
Type:
Application
Filed:
August 14, 2006
Publication date:
November 4, 2010
Inventors:
Jiang Liu, Michael Richard Johnston, Xiao Yu Wu
Abstract: The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water .gtoreq.0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.
Abstract: Compositions of nanoparticles functionalized with at least one net positively charged group and at least one net negatively charged group, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core and a shell. The shell comprises a plurality of silane moieties; at least one silane moiety of the plurality is functionalized with a net positively charged group and at least one silane moiety of the plurality is functionalized with a net negatively charged group.
Type:
Application
Filed:
April 29, 2009
Publication date:
November 4, 2010
Applicant:
GENERAL ELECTRIC COMPANY
Inventors:
Peter John Bonitatibus, JR., Matthew David Butts, Robert Edgar Colborn, Amit Mohan Kulkarni, Bruce Allan Hay, Andrew Soliz Torres, Brian Christopher Bales, Michael Ernest Marino
Abstract: The invention provides compositions and method for delivering a therapeutic or diagnostic agent to a disease site in a mammal, the method comprising administering to the mammal a therapeutically or diagnostically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises the therapeutic or diagnostic agent coupled to a Procaspase 8 polypeptide and a pharmaceutically acceptable carrier.
Abstract: A bioactive PMMA (polymethylmethacrylate) bone cement contains a powder component and a reactive monomer liquid, wherein the powder component and the reactive monomer liquid when mixed with one another react with one another and form a polymer-based solid material. The powder component contains particulate polymer powder of polymethylmethacrylates; a radical starter; and anionic copolymer nanoparticles. The anionic copolymer nanoparticles are distributed in nano-particulate form within the particulate powder component or coated as a film on particles of the particulate polymer powder.
Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.
Abstract: The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof.
Type:
Application
Filed:
September 26, 2008
Publication date:
October 21, 2010
Applicants:
MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Inventors:
Omid C. FAROKHZAD, Jianjun CHENG, Benjamin A. TEPLY, Robert S. LANGER, Stephen E. ZALE
Abstract: Compounds, compositions and methods for the diagnosis of Alzheimer's disease. Synthesized Glycerophosphocholine (GPC) may be used as a diagnostic aid to measure progression of Alzheimer's disease. GPC is a membrane phospholipid metabolite that is capable of binding specifically to the ?-turn of beta amyloid (A?) peptide. Compounds including non-radioactive, paramagnetic, and radioactive derivatives of GPC are presented. These compounds possess similar binding properties to original GPC molecules and are useful in medical magnetic resonance imaging and/or positron emission tomography applications. By employing these radiological techniques in conjunction with the compositions of the present invention, the diagnosis and assessment of the progression of Alzheimer's disease may be achieved.
Type:
Grant
Filed:
May 27, 2004
Date of Patent:
October 19, 2010
Inventors:
Jay W. Pettegrew, Richard J. McClure, Kanagasabai Panchalingam, Billy W. Day
Abstract: The invention relates to compounds of formula (I): and their use as targeting vectors that bind to receptors associated with angiogenesis. Such compounds may thus be used for diagnosis or therapy of, for example, malignant diseases, heart diseases, endometriosis, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma.
Abstract: Methods are presented that comprise the administration of a pharmaceutical composition comprising adenosine and dipyridamole, as well methods comprising the combined administration of dipyridamole administered as a bolus with adenosine given as an infusion, both at dosages below their respective single agent dosages, for detecting the presence and/or assessing the severity of myocardial ischemia during pharmacologic stress tests. The methods are useful for exploiting the vasodilating abilities of adenosine at doses at which side effects related to adenosine are substantially reduced while optimal coronary artery perfusion is achieved. Also presented are compositions, unit dosage forms, and kits that are useful in performing the methods.
Abstract: An optically matching medium (6) for use in a device for examining turbid media is provided. The optically matching medium (6) comprises an absorber component (8) providing the optically matching medium with predetermined absorption properties. The absorber component (8) is selected such that the optical properties of the optically matching medium (6), with respect to electromagnetic radiation having a wavelength between 650 nm and 900 nm, substantially match the optical properties of a turbid medium (1) to be examined. The absorber component (8) comprises a dye or pigment approved for use in cosmetics, food, and/or drugs.
Type:
Application
Filed:
October 28, 2008
Publication date:
October 7, 2010
Applicant:
KONINKLIJKE PHILIPS ELECTRONICS N.V.
Inventors:
Antonius Wilhelmus Maria De Laat, Martinus Bernardus Van Der Mark
Abstract: Compositions and methods for manufacturing polymers are disclosed. Compositions include novel plastics, including films and shaped forms comprising polymer matrices that are biologically compatible and biodegradable. Such plastics may comprise polymers derived from natural sources. Further, such plastics are useful in biological systems for wound repair, implants, stents, drug encapsulation and delivery, and other applications. The disclosed methods comprise mild manufacturing processes such that various additives, such as biologically active proteins, sugars, lipids, and the like may be incorporated into the polymer matrix without subsequent loss of bioactivity during processing. Additionally, methods of manufacture for controlling mechanical properties, such as elasticity, pliancy, and the porosity of such plastics are disclosed.
Type:
Application
Filed:
July 28, 2006
Publication date:
October 7, 2010
Inventors:
Phil G. Campbell, Lee E. Weiss, Jason Smith
Abstract: A method for visualizing a blood clot or plaque disposed within a body lumen comprising: binding a contrasting complex comprising a contrast material and a thrombolytic material or a clot dissolving agent to the blood clot or plaque; and visualizing the blood clot or plaque over a period time by a visualizing system.
Abstract: Disclosed are novel peptides that are useful, for example, for detecting target proteins having a ?-sheet secondary structure which may be associated with a disease, and for diagnosing and treating such a disease. Related methods and kits also are disclosed.
Type:
Application
Filed:
January 28, 2010
Publication date:
September 16, 2010
Inventors:
D. Roxanne Duan, Jonathan R. Moll, Alan Rudolph, Renee Wegrzyn
Abstract: Radio-opaque biodegradable compositions are formed by modifying terminal groups of synthetic and natural biodegradable polymers such as polylactones with iodinated moieties. The biodegradable property of the compositions renders them suitable for use in medical field such as drug delivery, imaging. Compounds disclosed in this invention exist as neat liquid. Certain compositions disclosed in this invention form hydrophobic iodine rich domains when dissolved in water, such domains provide better contrasting properties as well as ability to dissolve hydrophobic bioactive drugs. Certain iodinated moieties disclosed in the invention are capable of cross linking natural proteins in situ in presence of suitable catalysts and co-catalysts.
Type:
Grant
Filed:
August 9, 2004
Date of Patent:
September 7, 2010
Assignee:
Pathak Holdings, LLC
Inventors:
Chandrashekhar P. Pathak, Sanjay M. Thigle
Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidyserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.
Type:
Grant
Filed:
February 13, 2009
Date of Patent:
September 7, 2010
Assignee:
Board of Regents, The University of Texas System
Inventors:
Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
Abstract: Example compositions of liposomes with hydrophilic polymers on their surface, and containing relatively high concentrations of contrast-enhancing agents for computed tomography are provided. Example pharmaceutical compositions of such liposomes, when administered to a subject, provide for increased contrast of extended duration, as measured by computed tomography, in the bloodstream and other tissues of the subject. Also provided are example methods for making the liposomes containing high concentrations of contrast-enhancing agents, and example methods for using the compositions.
Type:
Grant
Filed:
November 10, 2006
Date of Patent:
August 31, 2010
Assignee:
Marval Biosciences, Inc.
Inventors:
Ananth Annapragada, Ravi V. Bellamkonda, Eric Hoffman, Chandra Vijayalakshmi
Abstract: A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.
Type:
Application
Filed:
February 17, 2010
Publication date:
August 19, 2010
Applicant:
Cornell Research Foundation, Inc.
Inventors:
Neil Bander, Joseph Osborne, Stanley J. Goldsmith, Shankar Vallabhajosula
Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.
Type:
Application
Filed:
April 5, 2010
Publication date:
August 19, 2010
Inventors:
Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Arsenio Fialho
Abstract: Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution.
Type:
Application
Filed:
December 5, 2008
Publication date:
August 12, 2010
Inventors:
Ananth Annapragada, Ravi Bellamkonda, Efstathios Karathanasis, Russell M. Lobovitz
Abstract: The present invention provides compounds of the formula X—R1-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)-R3(Y)-NR4R5; or R1(X)-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)-R3(Y)-NR4R5, in which X is a hard acid cation chelator, a soft acid cation chelator or Ac-, R1, R2 and R3 are independently selected from a covalent bond or one or more D-amino acids that can be the same or different, Y is a hard acid cation chelator, a soft acid cation chelator or absent, Z is a hard acid cation chelator, a soft acid cation chelator or absent, and A and B are haptens or hard acid cation chelators and can be the same or different, and R4 and R5 are independently selected from the group consisting of hard acid cation chelators, soft acid cation chelators, enzymes, therapeutic agents, diagnostic agents and H. The present invention also provides methods of using these compounds and kits containing the compounds.
Type:
Application
Filed:
December 18, 2006
Publication date:
August 12, 2010
Inventors:
William J. McBride, David M. Goldenberg
Abstract: The present invention discloses a radiographic contrasting agent containing multiple aromatic groups, each of which is substituted with at least three halogen atoms. The radiographic contrasting agent can initiate a polymerization process. The present invention also discloses a radio-opaque polymeric material that comprises a biodegradable polymer having at least one radiographic contrasting moiety covalently attached thereto. The radio-opaque polymeric material provides enhanced contrasting intensity in radiographic imaging. The radio-opaque polymeric material can be applied on at least a portion of one surface of a medical device. The radio-opaque polymeric material can also be used to construct a medical device, a component thereof, or a portion of a component thereof.
Abstract: The present invention describes polymer nanoparticles with a cationic surface potential, in which both hydrophobic and hydrophilic pharmaceutically active substances can be encapsulated. The hydrophilic and thus water-soluble substances are encapsulated in the particle core by co-precipitation through ionic complexing with a charged polymer. Both therapeutic agents and diagnostic agents can be used as pharmaceutically active substances for encapsulation. The cationic particle surface permits stable, electrostatic surface modification with partially oppositely charged compounds, which can contain target-specific ligands for improving passive and active targeting.
Abstract: A method for treating a joint affected by pain that involves injecting an agent that includes resiniferatoxin (RTX) dissolved in a physiologically suitable solvent locally into the intracapsular region or the bursa of the joint affected by pain.
Abstract: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing a triamine alkyl central moiety allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging and to contrast media containing such compounds.
Type:
Application
Filed:
June 27, 2008
Publication date:
July 29, 2010
Inventors:
Lars-Goran Wistrand, Duncan George Wynn, Ian Martin Newington, Veronique Morisson-Iveson
Abstract: A pharmaceutical of the general formula Z—(L)n-V, wherein V denotes an amino acid sequence X1-X2-Val-Tyr-Ile-His-Pro-X8-X9-X10; L denotes a bond or a linker; Z denotes a group that optionally can carry an imaging moiety M; X1 denotes an amino acid; X2 denotes Arg or N-alkylated Arg or a mimetic of Arg; X8, X9 and X10 constitute an ACE cleavage site; Z forms a bond with the amino acid X1 optionally through the linker L; and M where denotes an imageable moiety capable of detection either directly or indirectly in a diagnostic imaging procedure.
Abstract: The subject invention pertains to a method of detecting colon disorders including inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, based on underexpression of Lipopolysaccharide Responsive Beige-like Anchor (LRBA). Advantageously, the invention may be used to test for inflammatory bowel disease using a blood sample from a subject before a more invasive test for colon disorders is employed. The invention also pertains to methods of treating a colon disorder in a subject in which the colon disorder is detected.
Abstract: The present invention relates to a method of stabilizing a low molecular weight compound in a cationic liposome, wherein said compound has a low solubility in a lipid membrane and/or a low permeability across a lipid membrane. Preferrably, the compound is modified in order to increase lipid membrane solubility and/or lipid membrane permeability. After delivery of the cationic liposome to a target site, particularly a target site in an organism, the modification is reversed and the low molecular weight compound may enact its desired activity.
Type:
Application
Filed:
December 22, 2009
Publication date:
July 15, 2010
Applicant:
MediGene AG
Inventors:
Heinrich Haas, Thomas Fichert, Brita Schulze, Toralf Peymann, Uwe Michaelis, Michael Teifel
Abstract: An aqueous negative contrast agent for CT imaging of the gastrointestinal tract and the preparation method thereof. The agent is used in biological and pharmaceutical field. Its components and the weight percent are: hydrogel matrix 0.01-1%, micro-/nano-particles of the materials with low densities 5-50%, stabilization agents 0.1-5%, the rest is deionized water. The preparation method is: stabilization agents are added into the hydrogel matrix made of natural or synthetic hydrophilic polymers, then micro-/nano-particles of the materials with low CT densities are added or prepared, and uniformly dispersed in the hydrogel matrix. The CT density of the resulted aqueous negative contrast agent for CT imaging of the gastrointestinal tract is ?30HU to ?500HU. It can decrease the CT density inside the intestine lumen to lower than ?30HU. The intestine wall can be depicted clearly and the CT signals intensities inside lumen are uniform.
Abstract: Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core, having a core surface essentially free of silica, and a shell attached to the core surface. The shell comprises at least one silane-functionalized zwitterionic moiety.
Type:
Application
Filed:
December 29, 2008
Publication date:
July 1, 2010
Applicant:
GENERAL ELECTRIC COMPANY
Inventors:
Matthew David Butts, Robert Edgar Colborn, Peter John Bonitatibus, JR., Amit Mohan Kulkarni, Bruce Allan Hay, Andrew Soliz Torres, Brian Christopher Bales, Michael Ernest Marino
Abstract: This document provides methods and materials related to assessing brain conditions within mammals. For example, methods and materials that can be used to determine whether or not a mammal (e.g., a human) with a brain aneurysm is likely to experience brain aneurysm rupture are provided.
Type:
Application
Filed:
March 2, 2010
Publication date:
June 24, 2010
Applicant:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Abstract: The present invention relates to biodegradable biocompatible polyketals, methods for their preparation, and methods for treating animals by administration of biodegradable biocompatible polyketals. In one aspect, a method for forming the biodegradable biocompatible polyketals comprises combining a glycol-specific oxidizing agent with a polysaccharide to form an aldehyde intermediate, which is combined with a reducing agent to form the biodegradable biocompatible polyketal. The resultant biodegradable biocompatible polyketals can be chemically modified to incorporate additional hydrophilic moieties. A method for treating animals includes the administration of the biodegradable biocompatible polyketal in which biologically active compounds or diagnostic labels can be disposed. The present invention also relates to chiral polyketals, methods for their preparation, and methods for use in chromatographic applications, specifically in chiral separations.
Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.
Type:
Application
Filed:
September 15, 2009
Publication date:
June 10, 2010
Inventors:
Edward S. Boyden, Daniel B. Cook, Roderick A. Hyde, Eric C. Leuthardt, Nathan P. Myhrvold, Elizabeth A. Sweeney, Lowell L. Wood, JR.
Abstract: We describe a method for opening the blood-brain barrier (BBB) using ultrasound and preformed microbubbles. With this method, diagnostic or therapeutic agents may be administered to the brain. This method can open a focal region of the BBB and administer agents in a targeted fashion or the method can open large regions (or the entirety) of the brain for more global administration of agents. In one embodiment, the method can be used to administer contrast agents (e.g., agents that increase or decrease the magnetic resonance imaging signal) to the brain and thereby improve the quality or information content of imaging data. In another embodiment, a standard clinical diagnostic ultrasound scanner can be used to open specific regions of the BBB and administer diagnostic or therapeutic agents. Importantly, this invention can open the BBB in a non-destructive/non-invasive fashion, allowing the subject to be awake and suffer no detectable side effects.
Type:
Application
Filed:
October 22, 2009
Publication date:
June 10, 2010
Inventors:
G. Allan Johnson, Gabriel Howles-Banerji, Kristin Frinkley Bing, Kathryn Nightingale, Mark Palmeri
Abstract: Contemplated substituted arylpiperazinyl compounds, and most preferably 18F-Mefway, exhibit desirable in vitro and in vivo binding characteristics to the 5-HT1A receptor. Among other advantageous parameters, contemplated compounds retain high binding affinity, display optimal lipophilicity, and are radiolabeled efficiently with 18F-fluorine in a single step. Still further, contemplated compounds exhibit high target to non-target ratios in receptor-rich regions both in vitro and in vivo, and selected compounds can be effectively and sensitively displaced by serotonin, thus providing a quantitative tool for measuring 5-HT1A receptors and serotonin concentration changes in the living brain.
Type:
Grant
Filed:
January 24, 2007
Date of Patent:
June 8, 2010
Assignee:
The Regents of the University of California
Abstract: A method for assessing cancer susceptibility to molecular targeted therapy. Also provided are methods for in vivo panning of diverse molecules for isolation of targeting ligands that specifically bind an apoptotic cell associated with a responding tumor, targeting ligands identified by the panning methods, and diagnostic and imaging uses therefor.
Abstract: Targeting polypeptide imaging agents, methods employing the agents, and kits employing the agents are provided. The targeting polypeptide imaging agents may have at least one targeting polypeptide and at least one contrast enhancing imaging agent.
Type:
Application
Filed:
May 18, 2007
Publication date:
May 27, 2010
Applicant:
THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
Abstract: Embodiments provide a noninvasive quantitative method for detecting extent and/or types of fibrosis in the heart. In embodiments, information pertaining to the extent and/or types of fibrosis may aid in the diagnosis of specific cardiac diseases and heart failure and/or may assist in determining suitable treatment options. Embodiments provide methods and apparatuses for determining the extent of fibrosis in viable and nonviable myocardium, which may then be correlated to heart disease and failure. Thus, in an embodiment, a method of screening individuals for the purpose of heart disease or heart failure prevention may be provided using the detection methodology described herein.
Type:
Application
Filed:
April 11, 2008
Publication date:
May 27, 2010
Applicant:
Oregon Health & Science University
Inventors:
Michael Jerosch-Herold, Sumeet S. Chugh